Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Midomafetamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : ATAI Life Sciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Atai Life Sciences Announces Initiation of Phase 1 Trial for its MDMA Derivative, EMP-01
Details : The Phase 1 study is designed to evaluate the safety and tolerability of EMP-01 (3,4-methylenedioxymethamphetamine) in participants, as well as assess the usability and acceptability of the IDEA-1 app in delivering “set and setting” content to partic...
Brand Name : EMP-01
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 27, 2022
Lead Product(s) : Midomafetamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : ATAI Life Sciences
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?